ABSTRACT
Primary cutaneous CD4+ small-/medium-sized T-cell lymphoproliferative disorder is usually characterized by nodules and plaques affecting the upper part of the body. The present case presented with a large, single tumor located on a lower extremity. The patient did not respond to surgical therapy but responded to cyclophosphamide, methotrexate, and radiotherapy.
ABSTRACT
Connective tissue diseases, defined as chronic, multi-system autoimmune dysfunctions, occur predominantly in women of childbearing age. Pregnancy, as a specific state of hormonal and immunological diversity, may involve adverse influence on maternal disease activity, causing remission or exacerbation necessitating appropriate therapy. In the first part of the article the influence of female hormones on the immunological cells is presented, as well as their role in the autoimmunological process. The special emphasis is put on most frequent connective tissue diseases among young women- systemic lupus erythematosus and antiphospholipid syndrome. The article also highlights the risk of potential obstetric complications, the gravity of careful planning, restrictive monitoring and necessary treatment to minimalize the risk of intricacy.
Subject(s)
Antiphospholipid Syndrome/immunology , Antiphospholipid Syndrome/therapy , Lupus Erythematosus, Systemic/immunology , Lupus Erythematosus, Systemic/therapy , Pregnancy Complications/immunology , Pregnancy Complications/therapy , Adult , Estrogens/immunology , Female , Humans , PregnancyABSTRACT
Pregnancy in women with connective tissue diseases is classified as a high risk pregnancy. Therefore, a proper treatment which is safe both for mother and child, arouses a problem. The second part of the article presents main pregnancy complications among women with systemic sclerosis, rheumatoid arthritis, ankylosing spondylitis and dermatomyositis. General groups of medications are discussed, which are most frequently used in treatment of pregnant women with connective tissue diseases. Furthermore, the article presents treatment schedule which obtained the United States Food and Drug Administration (FDA) recommendation. Nowadays, advancing technology and treatment improved outcomes in connective tissue diseases pregnancies.
